Search
Aurothioglucose
go.drugbank.com/drugs/DB09121ApprovedWithdrawncompounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far
Soybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalSoybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use.
Azelastine
go.drugbank.com/drugs/DB00972ApprovedInvestigational[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.
Alprazolam
go.drugbank.com/drugs/DB00404ApprovedIllicitInvestigational[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148]
Lamotrigine
go.drugbank.com/drugs/DB00555ApprovedInvestigationalLamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries.
Acamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigationalIt was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Bazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIn 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as
Triethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]
Aluminum chloride
go.drugbank.com/drugs/DB11081ApprovedInvestigationalIn antiperspirant products, FDA approves the use of aluminum chloride as an active ingredient up to 15%, calculated on the hexahydrate form, in an aqueous solution nonaerosol dosage form [L2012].